Skip to content

SCREENER CHART SD50 CALENDAR NEWS

...

Arrowhead Pharmaceuticals, Inc. (ARWR) Stock · SELL · CRISIS | LOPJLB

Arrowhead Pharmaceuticals, Inc. (ARWR)

Healthcare · Biotechnology · NASDAQ · US

$62.75+3.31%Close

SELLCRISIS · day 19

ARWR▼ SELL

$62.75+3.31%

Overview FinancialsFin EarningsEarn Analyst & RatingsAnalyst News Holders & ETFsHold Options

Key stats

Short interest · FINRA settlement 2026-09-30

Market cap: $8.8B
Beta: 1.30
P/E (TTM): -27.47

Short % float: 8.76%
Days to cover: 4.0
SI change: +16.1%

1W: -2.24%
1M: -24.18%

vs SPY 1W: -3.40%
vs SPY 1M: -27.17%

Industry peers

FMP comparable companies · ranked by market cap

ALNYSELLAlnylam Pharmaceuticals, Inc.$31.1BRECOVERYQ 28$232.68+3.63%
IONSSELLIonis Pharmaceuticals, Inc.$7.5BRECOVERYQ 8$45.28+4.57%
WVESELLWave Life Sciences Ltd.$682MCRISISQ 7$3.46-0.29%

Prediction markets

Kalshi · Polymarket · … linked

Full prediction markets →

Loading markets…

Company

Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive…

Employees: 711
Headquarters: US
Founded: 1993
Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares out: 140.9M
Float: 87.2%

arrowheadpharma.com ↗

Key executives

Christopher R. Anzalone — Chairman, Chief Executive Officer & President

Patrick O'Brien — COO & Secretary

Daniel J. Apel — Chief Financial Officer

SEC filings

EDGAR · CIK 8794070 · ARWR

All filings
10-K
10-Q
8-K
Form 4

Analyst consensus

Buy

Bullish1672.7%

Neutral627.3%

Bearish00.0%

L $46.00Avg $100.63H $126.00

Target$100.63+60.37%

Last$62.75

Company news

businesswire.com · 3d ago

Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia

defenseworld.net · 4d ago

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Breaks Below 200 Day Moving Average – Here’s Why

seekingalpha.com · 8d ago

Arrowhead Pharmaceuticals: The Fast-Follower Math Behind A $215 Million Voucher

businesswire.com · 11d ago

Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies

marketbeat.com · 22d ago

Arrowhead Pharmaceuticals Spotlights Dual-Target RNAi Data, Plozasiran Launch Progress

marketbeat.com · 22d ago

Arrowhead Pharmaceuticals Eyes SHTG Filing as RNAi Pipeline Expands

seekingalpha.com · 24d ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript

seekingalpha.com · 25d ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

gurufocus.com · 25d ago

Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

businesswire.com · 25d ago

Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

seekingalpha.com · 30d ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

fool.com · 34d ago

Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million

businesswire.com · 37d ago

Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences

defenseworld.net · 37d ago

Benjamin Edwards Inc. Makes New $721,000 Investment in Arrowhead Pharmaceuticals, Inc. $ARWR

seekingalpha.com · 40d ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses SHASTA-3 and SHASTA-4 12-Month Results for Plozasiran in Severe Hypertriglyceridemia Transcript

marketbeat.com · 40d ago

Arrowhead's Plozasiran Cuts Triglycerides, Pancreatitis Risk in Phase 3 Trials

gurufocus.com · 41d ago

Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia

businesswire.com · 41d ago

Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia

businesswire.com · 47d ago

Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress

defenseworld.net · 48d ago

Deutsche Bank AG Invests $12.16 Million in Arrowhead Pharmaceuticals, Inc. $ARWR

Market news & ticker search · RSS for ARWR

LOPJLB

Independent quant research on U.S. equities & ETFs. Not personalized advice.

Product

Screener Chart Compare SD50 Thesis News Calendar

Desk

Market Heatmap Market Hours FOMC Desk Treasury Rates Congress Trades Prediction Markets

Research

How It Works Methodology Track Record Editorial Blog Changelog

Ledgers

Bull Spreads Cash-Secured Puts Covered Calls Long Puts Long Calls

Screeners

CEF Screener REIT Screener BDC Screener Preferred Screener Dividend Screener ETF Screener Crypto Screener S&P 500 Screener

Company

Pricing About Contact

Agents

GitHub·Research Chat·MCPENT·Developers

© 2026 LOPJLB Research. All rights reserved.

@lopjlb contact@lopjlb.com

RANGE

LOPJLB.COM

OHLC🔒EMALEVELS🔒STOP🔒FLIP🔒52WSIGNALS🔒BUY🔒SELL🔒EXH🔒EXH ZONE🔒BEST